Ovid Therapeutics Relocates Principal Executive Offices
Ticker: OVID · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1636651
| Field | Detail |
|---|---|
| Company | Ovid Therapeutics Inc. (OVID) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $500,000, $1.07 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-address, 8-k
TL;DR
Ovid Therapeutics moved its main office to NYC. New address: 441 Ninth Ave, 14th Fl, NY, NY 10001.
AI Summary
Ovid Therapeutics Inc. announced on September 8, 2024, a change in its principal executive offices to 441 Ninth Avenue, 14th Floor, New York, NY 10001. The company also reported its fiscal year ends on December 31st. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
The relocation of principal executive offices can signal operational changes or strategic shifts for a company. Investors should monitor if this move impacts operational efficiency or costs.
Risk Assessment
Risk Level: low — This filing primarily concerns a change in business address, which typically carries low risk.
Key Numbers
- 10001 — ZIP Code (New York, NY)
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Registrant
- 441 Ninth Avenue, 14th Floor, New York, NY 10001 (location) — New Principal Executive Offices
- September 8, 2024 (date) — Date of earliest event reported
FAQ
What is the new address for Ovid Therapeutics Inc.'s principal executive offices?
The new address is 441 Ninth Avenue, 14th Floor, New York, NY 10001.
What is the exact name of the Registrant?
The exact name of the Registrant is Ovid Therapeutics Inc.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on September 8, 2024.
What is the state of incorporation for Ovid Therapeutics Inc.?
The state of incorporation is Delaware.
What is the fiscal year end for Ovid Therapeutics Inc.?
The fiscal year end is December 31st.
Filing Stats: 1,142 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2024-09-11 16:57:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Mar
- $500,000 — ovides for (i) an annual base salary of $500,000, (ii) an annual cash incentive bonus wi
- $1.07 — mber 9, 2024, (ii) an exercise price of $1.07 per share, and (iii) a term of 10 years
Filing Documents
- d869021d8k.htm (8-K) — 30KB
- d869021dex101.htm (EX-10.1) — 83KB
- g869021dsp1.jpg (GRAPHIC) — 6KB
- 0001193125-24-217302.txt ( ) — 267KB
- ovid-20240908.xsd (EX-101.SCH) — 3KB
- ovid-20240908_lab.xml (EX-101.LAB) — 18KB
- ovid-20240908_pre.xml (EX-101.PRE) — 11KB
- d869021d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Exhibit No. Description 10.1 Amended and Restated Executive Employment Agreement, dated September 9, 2024, between Ovid Therapeutics Inc. and Margaret Alexander. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer Dated: September 11, 2024